ICU Medical, Inc. (ICUI) Position Lifted by Wells Fargo & Company MN
Wells Fargo & Company MN increased its holdings in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 0.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 560,756 shares of the medical instruments supplier’s stock after acquiring an additional 5,044 shares during the period. Wells Fargo & Company MN owned approximately 2.81% of ICU Medical worth $104,217,000 as of its most recent SEC filing.
A number of other hedge funds have also made changes to their positions in the stock. BlackRock Inc. grew its holdings in ICU Medical by 0.6% during the second quarter. BlackRock Inc. now owns 1,780,976 shares of the medical instruments supplier’s stock worth $307,218,000 after acquiring an additional 11,046 shares during the period. Janus Henderson Group PLC acquired a new position in ICU Medical during the second quarter worth $247,072,000. Vanguard Group Inc. grew its holdings in ICU Medical by 16.3% during the second quarter. Vanguard Group Inc. now owns 1,304,282 shares of the medical instruments supplier’s stock worth $224,989,000 after acquiring an additional 183,133 shares during the period. JPMorgan Chase & Co. grew its holdings in ICU Medical by 3.5% during the third quarter. JPMorgan Chase & Co. now owns 432,281 shares of the medical instruments supplier’s stock worth $80,122,000 after acquiring an additional 14,537 shares during the period. Finally, Goldman Sachs Group Inc. grew its holdings in ICU Medical by 3.8% during the second quarter. Goldman Sachs Group Inc. now owns 388,473 shares of the medical instruments supplier’s stock worth $67,012,000 after acquiring an additional 14,270 shares during the period. 78.15% of the stock is currently owned by hedge funds and other institutional investors.
Shares of ICU Medical, Inc. (NASDAQ ICUI) opened at $204.00 on Tuesday. The company has a debt-to-equity ratio of 0.07, a current ratio of 4.65 and a quick ratio of 3.01. The firm has a market capitalization of $4,250.56, a price-to-earnings ratio of 82.80, a price-to-earnings-growth ratio of 3.39 and a beta of 0.36. ICU Medical, Inc. has a twelve month low of $127.00 and a twelve month high of $218.45.
ICU Medical (NASDAQ:ICUI) last posted its earnings results on Thursday, November 9th. The medical instruments supplier reported $1.12 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.77 by $0.35. The company had revenue of $343.20 million for the quarter, compared to analyst estimates of $328.56 million. ICU Medical had a return on equity of 4.81% and a net margin of 2.79%. ICU Medical’s revenue was up 253.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.35 earnings per share. equities research analysts forecast that ICU Medical, Inc. will post 3.95 EPS for the current fiscal year.
In other ICU Medical news, CEO Vivek Jain sold 2,200 shares of the company’s stock in a transaction on Monday, October 9th. The stock was sold at an average price of $190.91, for a total value of $420,002.00. Following the sale, the chief executive officer now owns 44,111 shares of the company’s stock, valued at $8,421,231.01. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Robert S. Swinney sold 1,000 shares of the company’s stock in a transaction on Tuesday, November 28th. The shares were sold at an average price of $215.10, for a total value of $215,100.00. Following the completion of the sale, the director now directly owns 13,330 shares in the company, valued at approximately $2,867,283. The disclosure for this sale can be found here. Insiders sold 121,447 shares of company stock worth $23,198,692 in the last three months. 13.60% of the stock is owned by corporate insiders.
A number of research analysts recently weighed in on ICUI shares. Gabelli reaffirmed a “buy” rating on shares of ICU Medical in a report on Friday, August 11th. BidaskClub lowered ICU Medical from a “hold” rating to a “sell” rating in a report on Thursday, August 24th. Zacks Investment Research lowered ICU Medical from a “hold” rating to a “strong sell” rating in a report on Tuesday, August 15th. Finally, KeyCorp started coverage on ICU Medical in a report on Tuesday, October 17th. They issued a “sector weight” rating on the stock. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. ICU Medical currently has an average rating of “Hold” and an average target price of $232.00.
ICU Medical Company Profile
ICU Medical, Inc is engaged in the development, manufacture and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, custom infusion sets, closed system transfer devices (CSTD) for the handling of hazardous drugs, advanced sensor catheters, needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems.
Receive News & Ratings for ICU Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.